Why did analysts lower their price targets for Bath & Body Works stock?

Analysts reduced Bath & Body Works' price targets due to underperforming third-quarter sales and earnings, and a downward revision of the company's full-year guidance.

What is the current outlook for Bath & Body Works' financial performance?

The outlook for Bath & Body Works is cautious, with management revising full-year guidance downward due to macroeconomic headwinds, indicating limited growth.

What product categories does Bath & Body Works specialize in?

Bath & Body Works specializes in products such as home fragrance, personal and body care, and soaps, operating under brands like Bath & Body Works and White Barn.

Home / Business and Economy / Analysts Slash Bath & Body Works Targets, Cite Weak Sales

Analysts Slash Bath & Body Works Targets, Cite Weak Sales

30 Nov, 2025

•

Summary

Analysts significantly reduced Bath & Body Works price targets.
Third-quarter sales and EPS missed company estimates.
Full-year guidance revised downward due to economic headwinds.

Analysts Slash Bath & Body Works Targets, Cite Weak Sales

Bath & Body Works (BBWI) is facing considerable analyst pessimism, with major firms like Jefferies and UBS sharply reducing their price targets. These downgrades follow the company's recent third-quarter earnings report, which revealed sales and earnings per share that fell short of expectations. Analysts highlighted the ongoing impact of macroeconomic challenges on the company's performance.

Further compounding concerns, Bath & Body Works management has revised its full-year financial guidance downward. Analysts attribute this revision to persistent economic headwinds that are hindering sales and limiting potential growth. One firm noted that the company is entering a multiyear recovery phase, with revised estimates showing a significant projected dip in earnings growth.

Founded in 1963 and headquartered in Ohio, Bath & Body Works operates specialty retail stores offering products such as home fragrance and personal care items. While the company holds investment potential, the current analyst outlook points to a period of constrained growth and significant business adjustments.